Mutant selection window and mutant prevention concentration for antimicrobial agents

Abstract

Abstract: Mutant prevention concentration (MPC) is the lowest concentration threshold that restricts the selection of all single-step (next-step) mutant subpopulations; and mutant selection window (MSW) is a concentration range extending from MIC to MPC, within which resistant mutants are predominately enriched. When serum drug level is below MIC, no mutant will be enriched because selective pressure is absent, and it will be hardly selected while above MPC mutants because double mutations are required for growth;when within MSW however, mutants are most likely to be selectively enriched even though the clinical treatment may be effective. This theory may provide new approaches for drastically reducing selection of resistance and formulating new strategies for proper antimicrobial use during therapy.

Key words: mutant prevention concentration, mutant selection window, antibiotic-resistance

CLC Number:

R34
R978.1

LI Yan-Yu, PEI Fei, ZHAO Xi-Lin, WANG Rui. Mutant selection window and mutant prevention concentration for antimicrobial agents[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(1): 1-7.

References

1 Drlica K.Antibiotic resistance:can we beat the bugs[J] ? Drug Discov Today, 2001;6:714-6
2 Levy SB.Multidrug resistance:a sign of the times[J]. N Engl J Med, 1998;38:1376-8
3 Zhao X.Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolones studies[J]. Clin Infect Dis, 2001;33:S147-56
4 Drlica K.A strategy for fighting antibiotic resistance[J]. ASM News, 2001;67:27-33
5 Drlica K.The future of fluoroquinolones[J]. Ann Med, 2000;32:585-7
6 Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquilonone concentration on selection of resistant mutants of mycobacterium bovis BCG and staphylococcus aureus[J]. Antimicro Agents Chemother, 1999;43:1756-8
7 Dong Y, Zhao X, Kreiswirth BN, et al. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2000;44:2581-4
8 Zhao X, Drlica K.Restricting the selection of antibiotic-resistant mutant bacteria:measurement and potential use of the mutant selection window[J]. J Infect Dis, 2002;185:561-5
9 Zhao J, Dong Y, Zhao X, et al. Selection of antibiotic-resistant bacterial mutants:allelic diversity among fluoroquilonone-resistant mutantions[J]. J Infect Dis, 2002;182:517-25
10 Nakamura S.Mechanisms of quinolone resistance[J]. J Infect Chemother, 1997;3:128-38
11 Baquero F, Negri MC.Strategies to minimize the development of antibiotic resistance[J]. J Chemother, 1997;9;29-37
12 Blondeau J M, Zhao X, Hansen J, et al. Mutant prevention concentration of fluoroquinolones for clinical isolates of streptococcus pneumoniae[J]. Antimicrob Agents Chemother, 2001;45:433-8
13 Hansen G, Metzler K, Drlica K, et al. Mutant prevention concentration for gemifloxacin with clinical isolates of streptococcus pneumoniae[J]. Antimicro Agents Chemother, 2003;47:440-1
14 Sindelar G, Zhao X, Liew A, et al. Mutant prevention concentration as a measure of fluoroquilonone potency against mycobacteria[J]. Antimicrob Agents Chemother, 2000;44:3337-43
15 Tao L, Zhao X, Li X, et al. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of mycobacterium smegmatis and staphylococcus aureus[J]. In press
16 Zhao X, Eisner W, Perl-Rosenthal N, et al. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxa- cin-susceptible or-resistant staphylococcus aureus[J]. Antimicrob Agents Chemother, 2003;47:1023-7
17 Li XY, Zhao XL, Drlica K.Selection of streptococcus pneumonia mutants having reduced susceptibility to moxifloxacin and levofloxacin[J]. Antimicro Agents Chemother, 2002;46:522-4
18 Tillotson G, Zhao X and Drlica K.Fluoroquilonenes as pneumococcal therpy:closing the barn door before the horse escapes[J]. Lancet Inf Dis, 2001;1:145-6
19 Drlica K, Malik M.Fluoroquilonones:action and resistance[J]. Curr Top Med Chem, 2003;3:249-82
20 Zhao XL, Chen X, Domagala J, et al. DNA topoisomerase targets of the fluoroquilonens:a strategy for avoiding bacterial resistance[J]. Proc Natl Sci USA, 1997;94:13991-6
21 Dong YZ, Chen X, Zhao XL, et al. Fluoroquinolone action against mycobacteria:effects of C-8 substituents on growth, survival and resistance[J]. Antimicro Agents Chemother, 1998;42:2978-84
22 Xu C, Kreiswirth BN, Sreevastan S, et al. Fluoroquinolones resistance associated with specific gray se mutations in clinical isolates in multidrug resistant my cobacterium tuberculosis[J]. J Infect Dis, 1996;174:1127-30
23 Vernon A, Burman W, Benator D, et al. Acquinred rifamy cin monoresistance in paients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid[J]. Lancet, 1999;353:1843-7
24 Firsov AA, Vostrov SN, Lubenko IY, et al. In vitro pharmacodynamics evaluation of the mutant selection window hypothesis using four fluoroquinolones against staphylococcus aureus[J]. Antimicrob Agents Chemother, 2003;47:1604-13
25 Pestova E, Beyer R, Cianciotto NP, et al. Contribution of topoisomerase Ⅳ and DNA grayse mutations in streptococcus pneumoniae to resistance to novel fluoroquilonones[J]. Antimicro Agents Chemother, 1999;43:2000-4
26 Sieradzki K, Roberts R, Haber S, et al. The development of the vancomy cin resistance in a patient with methicillin-resistant Staphylococuus aureus infection[J]. N Engl JMed, 1999;340:517-23
27 Craig WA.Pharmocokinetic pharmocosynamic parameters:rational for antibacterial dosing of mice and men[J]. Clin Infect Dis, 1998;26:1-12
28 Gould IM, MacKenzie FM, et al. Antibiotic exposure as a risk factor for emergence of resistance:the influence of concentration[J]. J ApplMicrob Sympo Suppl, 2002;92:78s-84s

[1]	HUANG Han, LIU Shi-kun. Discussion and considerations on the mutant prevention concentration and mutant selective window [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(1): 21-24.
[2]	CUI Jun-chang, LIU You-ning, WANG Rui, TONG Wei-hang, LIANG Bei-bei. Correlation of levofloxacin pharmacokinetic/pharmacodynamic parameters with selection of staphylococcus aureus resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(9): 989-992.
[3]	LI Zhao-xia, LIU You-ning, WANG Rui, TONG Wei-hang, CHENG Shi-hu. Preliminary study for narrowing mutant selection window of staphylococcus aureus by combination of levofloxacin and Vancomycin in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 911-914.
[4]	LI Zhao-xia, LIU You-ning, WANG Rui, TONG Wei-hang, CHENG Shi-hu. Studies on effect of drug concentration on selection of resistant mutants of staphylococcus aureus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 163-167.
[5]	LI Zhao-xia, LIU You-ning, WANG Rui, CUI Jun-chang, CHENG Shi-hu, TONG Wei-hang. In vitro studies of mutant prevention concentration and mutant selective window for staphylococcus aureus and its isogenic mutants strain [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 696-701.